JP2022544234A5 - - Google Patents

Info

Publication number
JP2022544234A5
JP2022544234A5 JP2022508506A JP2022508506A JP2022544234A5 JP 2022544234 A5 JP2022544234 A5 JP 2022544234A5 JP 2022508506 A JP2022508506 A JP 2022508506A JP 2022508506 A JP2022508506 A JP 2022508506A JP 2022544234 A5 JP2022544234 A5 JP 2022544234A5
Authority
JP
Japan
Prior art keywords
patient
compound
mutation
administration
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508506A
Other languages
English (en)
Japanese (ja)
Other versions
JP7818502B2 (ja
JP2022544234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045876 external-priority patent/WO2021030405A1/en
Publication of JP2022544234A publication Critical patent/JP2022544234A/ja
Publication of JP2022544234A5 publication Critical patent/JP2022544234A5/ja
Priority to JP2025144362A priority Critical patent/JP2025176093A/ja
Application granted granted Critical
Publication of JP7818502B2 publication Critical patent/JP7818502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508506A 2019-08-12 2020-08-12 胃腸間質腫瘍を治療するためのリプレチニブ Active JP7818502B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025144362A JP2025176093A (ja) 2019-08-12 2025-09-01 胃腸間質腫瘍を治療するためのリプレチニブ

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962885797P 2019-08-12 2019-08-12
US62/885,797 2019-08-12
US201962904198P 2019-09-23 2019-09-23
US62/904,198 2019-09-23
US201962926281P 2019-10-25 2019-10-25
US62/926,281 2019-10-25
US201962936018P 2019-11-15 2019-11-15
US62/936,018 2019-11-15
US202062968927P 2020-01-31 2020-01-31
US202062968945P 2020-01-31 2020-01-31
US62/968,927 2020-01-31
US62/968,945 2020-01-31
US202063023921P 2020-05-13 2020-05-13
US202063023936P 2020-05-13 2020-05-13
US63/023,921 2020-05-13
US63/023,936 2020-05-13
PCT/US2020/045876 WO2021030405A1 (en) 2019-08-12 2020-08-12 Ripretinib for treating gastrointestinal stromal tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025144362A Division JP2025176093A (ja) 2019-08-12 2025-09-01 胃腸間質腫瘍を治療するためのリプレチニブ

Publications (3)

Publication Number Publication Date
JP2022544234A JP2022544234A (ja) 2022-10-17
JP2022544234A5 true JP2022544234A5 (cg-RX-API-DMAC10.html) 2023-08-31
JP7818502B2 JP7818502B2 (ja) 2026-02-20

Family

ID=74566909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508506A Active JP7818502B2 (ja) 2019-08-12 2020-08-12 胃腸間質腫瘍を治療するためのリプレチニブ

Country Status (2)

Country Link
JP (1) JP7818502B2 (cg-RX-API-DMAC10.html)
IL (1) IL326329A (cg-RX-API-DMAC10.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025346A2 (pt) * 2017-05-30 2020-06-30 Deciphera Pharmaceuticals, Inc. uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas

Similar Documents

Publication Publication Date Title
JP2025176093A5 (cg-RX-API-DMAC10.html)
AU2017329090B9 (en) Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
JP2024133475A5 (cg-RX-API-DMAC10.html)
US12059410B2 (en) Methods of treating gastrointestinal stromal tumors
CN103764144B (zh) Pi3k抑制剂与mek抑制剂的协同组合
HRP20040996A2 (en) High drug load tablet
US11938116B2 (en) Treatments with nirogacestat
US11779572B1 (en) Methods of treating gastrointestinal stromal tumors
JP2018532811A (ja) ヒト免疫不全ウイルスを処置するための治療組成物
US20210369709A1 (en) EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN105744930A (zh) 包含他达拉非和氨氯地平的复合制剂
BR112020006783A2 (pt) formulação farmacêutica de comprimido em bicamadas
JP2019525948A5 (cg-RX-API-DMAC10.html)
CN113230411B (zh) 一种阿利沙坦酯或其盐与钙离子通道拮抗剂的复方药物组合物
JP2016512234A (ja) 薬学的複合製剤
CN120112291A (zh) 雌激素受体降解剂的给药方案
EP3054926A1 (en) Hiv treatment formulation of atazanavir and cobicistat
CN100475212C (zh) 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合
US20250025446A1 (en) Treatments with nirogacestat
JP2006508118A5 (cg-RX-API-DMAC10.html)
WO2025038481A1 (en) Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer
Quintás-Cardama et al. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase
JP2013142059A (ja) 腎細胞がん治療剤
CN109875999B (zh) 泊那替尼在kit突变型恶性黑色素瘤中的应用
WO2021067917A1 (en) Treatment of eosinophilic disorders with avapritinib